CTNMContineum Therapeutics Inc. - Ordinary Shares - Class A
CTNM
Contineum Therapeutics Inc. - Ordinary Shares - Class A142
Mkt Cap
$323.05MVolume
687,885.0052W High
$16.2552W Low
$3.35PE Ratio
-4.85CTNM Fundamentals
Price
$10.95Prev Close
$12.22Open
$10.9750D MA
$11.38Beta
0.46Avg. Volume
92,386.78EPS (Annual)
-$1.63P/B
1.77Rev/Employee
$0.00Contineum Therapeutics (NASDAQ:CTNM) Price Target Cut to $22.00 by Analysts at Royal Bank Of Canada
Royal Bank Of Canada lowered their target price on Contineum Therapeutics from $25.00 to $22.00 and set an "outperform" rating for the company in a research note on Friday...
MarketBeat·2h ago
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·2d ago
Contineum Therapeutics (NASDAQ:CTNM) Coverage Initiated at Leerink Partners
Leerink Partners initiated coverage on shares of Contineum Therapeutics in a report on Thursday. They issued an "outperform" rating and a $22.00 price objective on the stock...
MarketBeat·8d ago
Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·23d ago
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 235.81%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 235.8% in Contineum Therapeutics, Inc. (CTNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·4mo ago
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·11mo ago
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that...
Business Wire·11mo ago
Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that...
Business Wire·1y ago
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that...
Business Wire·1y ago
Contineum Therapeutics to Attend Upcoming Investor Conferences
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that...
Business Wire·1y ago